KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EPS (Weighted Average and Diluted) (2018 - 2025)

Castle Biosciences' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.07 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 121.88% year-over-year to -$0.07; the TTM value through Dec 2025 reached -$0.83, down 233.87%, while the annual FY2025 figure was -$0.83, 233.87% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Castle Biosciences, down from -$0.02 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.32 in Q4 2024 and bottomed at -$1.1 in Q1 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.21 (2023), against an average of -$0.31.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 1300.0% in 2023 before it skyrocketed 455.56% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.25 in 2021, then tumbled by 216.0% to -$0.79 in 2022, then skyrocketed by 88.61% to -$0.09 in 2023, then skyrocketed by 455.56% to $0.32 in 2024, then plummeted by 121.87% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's EPS (Weighted Average and Diluted) are -$0.07 (Q4 2025), -$0.02 (Q3 2025), and $0.16 (Q2 2025).